Stocks Health care LUCD
NASDAQ · Health careLucid Diagnostics Inc. (LUCD)
Lucid Diagnostics Inc. brought in $5.4M of revenue over the twelve months to June 30, 2026, up 24.9% from a year earlier. It posted a net loss of $52.3M. In fiscal 2025 capital spending exceeded operating cash flow by $46.7M. At June 30, 2026 it held $33.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
Key facts about Lucid Diagnostics Inc.
- Net worth
- Lucid Diagnostics Inc. has a market value (market cap) of $81.5M at the latest share price, and shareholders' equity of $10.9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $4.7M (+8.3% year on year), with a net loss of $58M. Over the 12 months to June 30, 2026: revenue $5.4M, net loss $52.3M.
- Cash flow
- In fiscal 2025 operations used $46.5M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 12, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Lucid Diagnostics Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Lucid Diagnostics Inc. does
Lucid Diagnostics Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker LUCD.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $4.7M | -$58M | -$0.69 | -$46.7M |
| 2024 | $4.3M | -$45.5M | -$1.05 | -$44.4M |
| 2023 | $2.4M | -$52.7M | -$1.26 | n/a |
| 2022 | $377K | -$56.2M | -$1.55 | -$32.9M |
| 2021 | $500K | -$28.1M | -$1.51 | -$18.5M |
| 2021 | n/a | -$8.3M | -$0.59 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where LUCD ranks in Health care
Latest SEC filings
What Lucid Diagnostics Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 22, 2026
- October 16, 2026
- September 22, 2026
- August 13, 2026
- August 12, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 27% to $1.5M versus the same quarter last year; diluted EPS -$0.08 versus -$0.08.
- June 24, 2026
- May 14, 2026
- May 13, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 52% to $1.3M versus the same quarter last year; diluted EPS -$0.17 versus -$0.52.
- April 30, 2026Additional proxy material DEFA14A
- April 30, 2026
Insider trades
What the people running Lucid Diagnostics Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| May 20, 2026 | Matheis DennisDirector | Bought | 245,000 | $245.3K |
| February 20, 2026 | Gordon Michael AdamGeneral Counsel and Secretary | Received as pay | 300,000 | - |
| February 20, 2026 | O'Neil ShaunPresident and COO | Received as pay | 620,000 | - |
| February 20, 2026 | Mcgrath Dennis MChief Financial Officer | Received as pay | 470,000 | - |
| February 20, 2026 | Cox James LDirector | Received as pay | 123,000 | - |
| February 20, 2026 | Lapidus StanleyDirector | Received as pay | 123,000 | - |
| February 20, 2026 | Palumbo John RDirector | Received as pay | 123,000 | - |
| February 20, 2026 | Sokolov Jacque JDirector | Received as pay | 123,000 | - |
Who owns LUCD
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
Largest institutional holders
Insiders
11 insiders reported holding 10,887,634 shares in total, about $4.4M at the last price.
| Holder | Shares |
|---|---|
| Aklog LishanChief Executive Officer, Director | 3,636,627 |
| Mcgrath Dennis MChief Financial Officer | 1,813,569 |
| O'Neil ShaunPresident and COO | 1,446,763 |
| Matheis DennisDirector | 1,033,443 |
| Gordon Michael AdamGeneral Counsel and Secretary | 1,000,000 |
| Cox James LDirector | 405,120 |
| Palumbo John RDirector | 338,000 |
| Lapidus StanleyDirector | 337,392 |
| Sparks Ronald MDirector | 320,460 |
| Sokolov Jacque JDirector | 320,460 |
Questions about LUCD
What does Lucid Diagnostics Inc. do?
Lucid Diagnostics Inc. is a company in the Health care sector, listed on NASDAQ as LUCD. Its shares trade on NASDAQ under the ticker LUCD.
What is Lucid Diagnostics Inc.'s net worth?
Lucid Diagnostics Inc. has a market value (market cap) of $81.5M at the latest share price, and shareholders' equity of $10.9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Lucid Diagnostics Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $52.3M on revenue of $5.4M.
How much revenue does Lucid Diagnostics Inc. make?
Over the twelve months to June 30, 2026 Lucid Diagnostics Inc. reported revenue of $5.4M. That is 24.9% more than a year earlier.
When did Lucid Diagnostics Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the unregistered share sale from October 22, 2026.
When is Lucid Diagnostics Inc.'s next earnings report?
Lucid Diagnostics Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare LUCD with
Follow LUCD
Get an email when Lucid Diagnostics Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Lucid Diagnostics Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.